Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Chronic Myeloid Leukemia – Current Treatment – Current Treatment: Physician Insights – Chronic Myeloid Leukemia (US)
The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…
Chronic Myeloid Leukemia – Current Treatment – Treatment Sequencing – Chronic Myeloid Leukemia (US)
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to position…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory DLBCL (US/EU)
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
